Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Retained Earnings (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Retained Earnings for 9 consecutive years, with $19000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 51.28% to $19000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19000.0 through Dec 2025, down 51.28% year-over-year, with the annual reading at $19000.0 for FY2025, 51.28% down from the prior year.
  • Retained Earnings hit $19000.0 in Q4 2025 for Sutro Biopharma, down from $33000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $106000.0 in Q3 2024 to a low of -$874.3 million in Q2 2025.
  • Historically, Retained Earnings has averaged -$309.8 million across 5 years, with a median of -$298.9 million in 2021.
  • Biggest five-year swings in Retained Earnings: crashed 1393303.33% in 2022 and later soared 100.02% in 2024.
  • Year by year, Retained Earnings stood at -$333.4 million in 2021, then skyrocketed by 99.81% to -$618000.0 in 2022, then tumbled by 90419.09% to -$559.4 million in 2023, then surged by 100.01% to $39000.0 in 2024, then plummeted by 51.28% to $19000.0 in 2025.
  • Business Quant data shows Retained Earnings for STRO at $19000.0 in Q4 2025, $33000.0 in Q3 2025, and -$874.3 million in Q2 2025.